OncLive TV

Rohan Garje, MD, discusses the impact of human papillomavirus status on survival outcomes in penile squamous cell carcinoma.

Michael Cecchini, MD, discusses interim data on the use of CM24 with nivolumab and NALIRIFOX in advanced/metastatic pancreatic ductal adenocarcinoma.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses findings from a National Cancer Database analysis on treatment outcomes of brain metastases from primary RCC.

Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

Ranee Mehra, MD, discusses long-term results for primary transoral surgery followed by reduced postoperative radiation in HPV-associated oropharynx cancer.

Jonathan Strosberg, MD, discusses safety data for 212Pb-DOTAMTATE in metastatic somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors.

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.

David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer.

Rene Adam, MD, PhD, discusses the use of chemotherapy and liver transplant in patients with definitively unresectable colorectal liver metastases.

Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Hetty E. Carraway, MD, MBA, discusses current treatment strategies available for patients with acute myeloid leukemia.

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Anthony V. D'Amico, MD, PhD, discusses the Decipher Genomic Classifier in prostate cancer treatment.

Ashwin Kishtagari, MD, discusses the selection process of JAK inhibitors for patients with myelofibrosis being treated in a community setting.

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Chiara Cremolini, MD, PhD, discusses the use of the xM and NeXT Personal Dx assays in the detection of minimal residual disease in patients with cancer.

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.

Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer.

Bradley McGregor, MD, discusses the DAD-IO trial of sacituzumab govitecan, enfortumab vedotin, and pembrolizumab in metastatic urothelial cancer.

Julia Foldi, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment paradigm for metastatic HER2-positive breast cancer.